Everyone knows it's just a waiting game.15 May 2026 09:07
The strong trend in pharma and biotech dealmaking, which has been ongoing for several years, should continue according to experts.
Speaking at the FT US Pharma and Biotech Summit in New York, Eric Tokat, partner at Centerview Partners, noted that in Q4 2025 and Q1 2026, there have been 34 significant transactions in the pharma and biotech space, adding that many of the deals have dealt with companies that have earlier-stage candidates compared to past years.
Moreover, Clive Meanwell, chairman and partner at Population Health Partners, believes that the strong deal-making environment is poised to continue for at least the next few years.
While dealmaking recently has focused on oncology and obesity, Meanwell sees this expanding into other areas, particularly central nervous system (CNS) assets